NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

INCY

Incyte Corp

Jul 02 • 04:00PM ET

68.17

Dollar change -0.56
Percentage change -0.81	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD IONS BMY MRK JNJ AMGN PFE LLY

| Held by: VTI VOO VB VBK RSP SPY IVV XBI USMV IBB

Scroll to Statements

Index	S&P 500	P/E	210.92	EPS (ttm)	0.32	Insider Own	1.40%	Shs Outstand	193.78M	Perf Week	0.92%
Market Cap	13.20B	Forward P/E	10.15	EPS next Y	6.72	Insider Trans	-1.82%	Shs Float	190.87M	Perf Month	4.38%
Enterprise Value	10.83B	PEG	2.15	EPS next Q	1.40	Inst Own	99.58%	Short Float	4.29%	Perf Quarter	11.92%
Income	21.27M	P/S	2.99	EPS this Y	426.69%	Inst Trans	4.96%	Short Ratio	4.02	Perf Half Y	-1.53%
Sales	4.41B	P/B	3.60	EPS next Y	18.53%	ROA	0.33%	Short Interest	8.19M	Perf YTD	-1.30%
Book/sh	18.93	P/C	5.48	EPS next 5Y	98.04%	ROE	0.47%	52W High	83.95 -18.80%	Perf Year	12.45%
Cash/sh	12.44	P/FCF	43.59	EPS past 3/5Y	-66.90% -40.36%	ROIC	0.57%	52W Low	53.56 27.28%	Perf 3Y	-11.88%
Dividend Est.	-	EV/EBITDA	36.57	Sales past 3/5Y	12.41% 14.46%	Gross Margin	91.16%	Volatility	3.17% 3.01%	Perf 5Y	-35.66%
Dividend TTM	-	EV/Sales	2.45	EPS Y/Y TTM	-88.78%	Oper. Margin	4.68%	ATR (14)	2.14	Perf 10Y	-35.26%
Dividend Ex-Date	-	Quick Ratio	2.00	Sales Y/Y TTM	17.13%	Profit Margin	0.48%	RSI (14)	52.32	Recom	2.24
Dividend Gr. 3/5Y	- -	Current Ratio	2.04	EPS Q/Q	6.97%	SMA20	-0.77%	Beta	0.71	Target Price	75.85
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	19.53%	SMA50	5.20%	Rel Volume	1.17	Prev Close	68.73
Employees	2617	LT Debt/Eq	0.01	Earnings	Apr 29 BMO	SMA200	0.31%	Avg Volume	2.04M	Price	68.17
IPO	Nov 04, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.55% 6.88%	Trades		Volume	2,374,621	Change	-0.81%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-16-25	Upgrade	Stifel	Hold → Buy	$107
Mar-18-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-18-25	Downgrade	Guggenheim	Buy → Neutral
Dec-17-24	Initiated	UBS	Neutral	$77
Oct-29-24	Upgrade	BofA Securities	Neutral → Buy	$68 → $90
Oct-01-24	Initiated	Wolfe Research	Outperform	$84
Sep-18-24	Downgrade	Truist	Buy → Hold	$83 → $74
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48
May-23-24	Initiated	Deutsche Bank	Hold	$55
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78
Dec-04-23	Upgrade	Guggenheim	Neutral → Buy	$86
Nov-21-23	Downgrade	Goldman	Buy → Neutral	$98 → $65
Jul-25-23	Initiated	Citigroup	Buy	$82
May-04-23	Downgrade	BofA Securities	Buy → Neutral	$84
Apr-10-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$81 → $79
Mar-24-23	Upgrade	SVB Securities	Underperform → Market Perform	$61
Jan-31-23	Initiated	Piper Sandler	Overweight	$100

Show Previous Ratings

Jul-02-25 04:30PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-25 09:33AM	Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? (Zacks)
Jun-30-25 09:15AM	Jim Cramer Highlights That Incyte's New CEO is an "Industry Veteran" (Insider Monkey)
Jun-27-25 01:14PM	Incyte Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
12:21PM	Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz (TipRanks)
04:45PM	Loading…
Jun-26-25 04:45PM	Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role? (Investor's Business Daily)
09:16AM	Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes (Investor's Business Daily)
07:30AM	Incyte Appoints Bill Meury Chief Executive Officer; Herv Hoppenot to Retire (Business Wire)
Jun-24-25 03:05AM	How Is Incytes Stock Performance Compared to Other Biotech Stocks? (Barchart)
Jun-23-25 09:53AM	FDA Extends INCY's Application for Opzelura Label Expansion (Zacks)
12:19AM	5 Revealing Analyst Questions From Incyte's Q1 Earnings Call (StockStory)
Jun-20-25 04:30PM	Update on FDA Review of Ruxolitinib Cream (Opzelura) for Children Ages 2-11 with Atopic Dermatitis (Business Wire)
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 03:39PM	Incyte Announces FDA Approval of Monjuvi (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma (Business Wire)
Jun-17-25 12:08PM	Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics (Zacks)
09:35AM	Loading…
09:35AM	Cisco upgraded, CoreWeave downgraded: Wall Streets top analyst calls (TipRanks)
Jun-16-25 08:27AM	QGEN Stock Rises in After Market Following Partnership With Incyte (Zacks) +5.12%
07:06AM	Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms (Medical Device Network)
Jun-15-25 05:49AM	Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches (Insider Monkey)
04:00AM	QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) (Business Wire)
03:15AM	Positive Late-Breaking Data for Incytes First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025 (Business Wire)
Jun-13-25 12:05PM	Specialised Therapeutics announces expanded partnership with Incyte (TipRanks)
Jun-12-25 06:45PM	Phase 3 Data for Incytes Retifanlimab (Zynyz) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet (Business Wire)
Jun-06-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:08PM	Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector? (MarketWatch)
11:31AM	Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-05-25 11:30AM	Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? (Zacks)
Jun-03-25 10:30AM	Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025 (Business Wire)
May-29-25 07:58PM	Analyst Report: Incyte Corporation (Morningstar Research)
11:30AM	Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report? (Zacks)
08:00AM	Loading…
May-27-25 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
May-22-25 12:02AM	3 Reasons INCY is Risky and 1 Stock to Buy Instead (StockStory)
May-20-25 05:06PM	S&P 500 Gains and Losses Today: FICO Stock Falls as Federal Housing Official Questions Pricing (Investopedia)
May-19-25 09:26AM	FDA approves Incytes retifanlimab combo for SCAC treatment (Pharmaceutical Technology)
May-16-25 10:51AM	Incyte Gets FDA Approval for Zynyz in New Cancer Indication (Zacks)
May-15-25 02:30PM	Incyte Announces FDA Approval of Zynyz (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States (Business Wire)
May-14-25 07:49AM	Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying (Insider Monkey)
May-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-06-25 01:13PM	Q1 2025 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 05:06AM	I Scanned The S&P 500 For GARP Stocks; Here's What I Found (Seeking Alpha)
May-01-25 08:00AM	Incyte to Present at Upcoming Investor Conference (Business Wire)
Apr-30-25 03:06AM	Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Apr-29-25 03:20PM	Analyst Report: Incyte Corporation (Morningstar Research)
12:53PM	Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript (Seeking Alpha)
11:04AM	INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales (Zacks)
09:30AM	Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings (Zacks)
09:03AM	3 Value Stocks Facing Headwinds (StockStory)
08:15AM	Incyte (INCY) Q1 Earnings and Revenues Top Estimates (Zacks)
07:29AM	Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers (StockStory)
07:12AM	Incyte: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs (Business Wire)
Apr-28-25 03:04AM	Incyte (INCY) Q1 Earnings Report Preview: What To Look For (StockStory)
Apr-25-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
08:00AM	Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 (Business Wire)
Apr-24-25 10:01AM	Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-23-25 11:03AM	Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
07:50AM	Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know (Zacks)
Apr-22-25 10:01AM	Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-10-25 08:00AM	Incyte to Report First Quarter Financial Results (Business Wire) -6.27%
Apr-08-25 09:15AM	AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis (Zacks) -5.51%
Apr-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
05:01AM	Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY) (StockStory)
Apr-04-25 08:50AM	Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Apr-01-25 05:05AM	3 Reasons INCY is Risky and 1 Stock to Buy Instead (StockStory)
Mar-26-25 07:30AM	Knight Therapeutics Announces Launch of Minjuvi (tafasitamab) in Mexico (GlobeNewswire)
Mar-25-25 06:20AM	Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now? (Zacks)
Mar-24-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)
Mar-22-25 06:46AM	What Moved Markets This Week (SeekingAlpha)
Mar-21-25 11:56AM	Why Incyte Stock Was Tanking This Week (Motley Fool)
09:01AM	1 Healthcare Stock on Our Watchlist and 2 to Brush Off (StockStory)
04:46AM	The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics (Zacks)
02:30AM	Incyte Had a Bad Week. Investors Are Used to It. (Barrons.com)
Mar-20-25 01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha)
12:45PM	Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More (Zacks)
Mar-19-25 08:06AM	Incyte price target lowered to $72 from $74 at Truist (TipRanks)
Mar-18-25 07:01PM	Analyst Report: Incyte Corporation (Morningstar Research)
08:05AM	Stoke CEO exits; Medicare drug price talks advance (BioPharma Dive)
05:32AM	Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires (Insider Monkey)
Mar-17-25 04:52PM	Incyte stock dives after drug trial disappoints investors (Yahoo Finance Video) -8.62%
04:32PM	S&P 500 Gains and Losses Today: Index Ticks Higher Ahead of This Week's Fed Decision (Investopedia)
04:11PM	Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive' (Investor's Business Daily)
02:09PM	Oil pressures, Robinhood, Incyte: Market Minute (Yahoo Finance Video)
01:52PM	Why Incyte (INCY) Stock Is Nosediving (StockStory)
01:11PM	Incyte stock hit 11% despite paediatric dermatology trials hitting target (Clinical Trials Arena)
12:00PM	Top Stock Movers Now: Intel, Netflix, Incyte, and More (Investopedia)
12:00PM	Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results (Investopedia)
11:21AM	Incyte Is Todays Worst S&P 500 Stock. Heres Why. (Barrons.com)
11:20AM	Nvidia, Netflix, Berkshire Hathaway, Baidu, Incyte, NCL, Affirm: Stocks to watch today (Quartz)
09:53AM	Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls (Benzinga)
09:16AM	Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive' (Investor's Business Daily)
08:40AM	Nvidia, Berkshire Hathaway, Baidu, Lockheed Martin, Incyte, NCL: Stocks to watch today (Quartz)
07:00AM	Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa (Business Wire)
Mar-12-25 11:30AM	Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-11-25 08:48AM	Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss (Benzinga)
Mar-10-25 01:38PM	Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps (Benzinga)
Mar-08-25 01:00PM	Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study (PR Newswire)
09:01AM	Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting (Business Wire)
Mar-07-25 04:30PM	Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-01-25 02:31PM	Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now? (Insider Monkey)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SHEILA DENTON	Officer	Jul 02 '25	Proposed Sale	68.61	599	41,097		Jul 02 04:27 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Option Exercise	58.06	1,795	104,218	28,299	Jun 05 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Sale	68.00	1,795	122,060	26,504	Jun 05 04:04 PM
SHEILA DENTON	Officer	Jun 03 '25	Proposed Sale	68.00	1,795	122,060		Jun 03 04:06 PM
Tray Thomas	Principal Accounting Officer	May 30 '25	Sale	65.71	963	63,279	22,654	Jun 03 04:00 PM
Tray Thomas	Principal Accounting Officer	Jun 02 '25	Sale	64.88	651	42,237	22,003	Jun 03 04:00 PM
THOMAS R TRAY	Officer	Jun 02 '25	Proposed Sale	64.88	651	42,237		Jun 02 04:26 PM
THOMAS R TRAY	Officer	May 30 '25	Proposed Sale	65.71	963	63,279		May 30 04:03 PM
Flannelly Barry P	EVP & General Manager US	Mar 14 '25	Sale	67.69	19,807	1,340,656	33,567	Mar 18 04:01 PM
BARRY FLANNELLY	Officer	Mar 14 '25	Proposed Sale	67.69	19,807	1,340,728		Mar 14 04:11 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Option Exercise	58.06	599	34,778	26,447	Mar 06 04:56 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Sale	69.99	599	41,924	25,848	Mar 06 04:56 PM
SHEILA DENTON	Officer	Mar 04 '25	Proposed Sale	69.99	599	41,924		Mar 04 05:12 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Option Exercise	58.06	9,574	555,866	39,917	Feb 28 06:34 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Sale	74.07	14,069	1,042,136	25,848	Feb 28 06:34 PM
SHEILA DENTON	Officer	Feb 26 '25	Proposed Sale	74.07	14,069	1,042,138		Feb 26 04:04 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 21 '25	Sale	72.69	12,352	897,867	66,967	Jan 22 04:05 PM
STEVEN STEIN	Officer	Jan 21 '25	Proposed Sale	72.69	12,352	897,906		Jan 21 04:03 PM
Tray Thomas	Principal Accounting Officer	Dec 13 '24	Sale	70.64	650	45,916	23,962	Dec 17 12:37 PM
Tray Thomas	Principal Accounting Officer	Dec 16 '24	Sale	69.31	650	45,052	23,312	Dec 17 12:37 PM
THOMAS R TRAY	Officer	Dec 16 '24	Proposed Sale	69.31	650	45,052		Dec 16 04:04 PM
Iyengar Vijay K	EVP, GMAPPS	Nov 29 '24	Sale	75.38	6,043	455,544	30,658	Dec 03 12:52 PM
VIJAY IYENGAR	Officer	Nov 29 '24	Proposed Sale	75.39	6,043	455,555		Nov 29 01:28 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Option Exercise	70.03	3,680	257,719	61,722	Nov 08 12:48 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Sale	79.68	3,680	293,210	58,042	Nov 08 12:48 PM
BARRY FLANNELLY	Officer	Nov 06 '24	Proposed Sale	79.68	3,680	293,210		Nov 06 04:15 PM
Tray Thomas	Principal Accounting Officer	Sep 12 '24	Sale	62.94	572	36,002	24,825	Sep 16 01:25 PM
Tray Thomas	Principal Accounting Officer	Sep 13 '24	Sale	63.37	382	24,207	24,443	Sep 16 01:25 PM
Dickinson Jonathan Elliott	EVP, General Manager, Europe	Sep 12 '24	Sale	62.36	8,450	526,948	36,390	Sep 16 01:24 PM
THOMAS R TRAY	Officer	Sep 13 '24	Proposed Sale	63.37	382	24,207		Sep 13 04:06 PM
JONATHAN ELLIOTT DICKINSON	Officer	Sep 12 '24	Proposed Sale	62.36	8,450	526,930		Sep 12 04:17 PM
Stein Steven H	EVP & Chief Medical Officer	Aug 12 '24	Sale	60.63	11,608	703,793	90,011	Aug 14 03:37 PM
STEVEN STEIN	Officer	Aug 12 '24	Proposed Sale	60.63	11,608	703,771		Aug 12 04:39 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 25 '24	Sale	70.00	15,571	1,089,970	36,701	Jul 29 03:50 PM
Flannelly Barry P	EVP & General Manager US	Jul 16 '24	Sale	64.19	1,306	83,832	58,042	Jul 17 12:24 PM
Flannelly Barry P	EVP & General Manager US	Jul 09 '24	Sale	60.00	8,148	488,880	50,534	Jul 11 12:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INCY

Incyte Corp

Upgrade your FINVIZ experience